Publications by John Petkau
2006
. Liver test abnormalities in multiple sclerosis: Findings from placebo-treated patients. Neurology. AAN Enterprises; 2006; 67: 1291–1293.
2005
. Predicting gadolinium enhancement status in MS patients eligible for randomized clinical trials. Neurology. AAN Enterprises; 2005; 65: 1447–1454.
. Evaluation of asymptotic approximations for a two-stage Bernoulli bandit. Journal of Statistical Planning and Inference. Elsevier; 2005; 130: 133–148.
. Application of hidden Markov models to multiple sclerosis lesion count data. Statistics in Medicine. Wiley Online Library; 2005; 24: 2335–2344.
2004
. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing/remitting multiple sclerosis. Multiple Sclerosis. 2004; 10: 715.
. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Multiple Sclerosis. Sage Publications; 2004; 10: 126–138.
. Air pollution and cardiac arrhythmias in patients with implantable cardioverter defibrillators. Inhalation Toxicology. Taylor & Francis; 2004; 16: 353–362.
. A case-crossover analysis of particulate air pollution and cardiac arrhythmia in patients with implantable cardioverter defibrillators. Inhalation Toxicology. Taylor & Francis; 2004; 16: 363–372.
2003
. Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry. 2003; 74: 1162.
. Neutralising antibodies during treatment of secondary progressive multiple sclerosis with interferon beta-1b. Neurology. 2003; 61: 1025.
. Neutralizing antibodies during treatment of secondary progressive multiple sclerosis with interferon β-1b. Neurology. AAN Enterprises; 2003; 60: 37–43.
. Air pollution and daily mortality in a city with low levels of pollution. Environmental Health Perspectives. National Institute of Environmental Health Science; 2003; 111: 45-51.
. Optimal group sequential designs for the Anscombe-Colton model. In Mathematical Statistics and Applications: Festschrift for Constance van Eeden. IMS Lecture Notes - Monograph Series; 2003. pp. 291–315.
. Statistical approaches to assessing the effects of neutralizing antibodies IFNβ-1b in the pivotal trial of relapsing-remitting multiple sclerosis. Neurology. AAN Enterprises; 2003; 61:Supplement 5: S35–S37.
2002
. Exposure misclassification and threshold concentrations in time series analyses of air pollution health effects. Risk Analysis. Wiley Online Library; 2002; 22: 1183–1193.
2001
. Exposure of chronic obstructive pulmonary disease patients to particles: Respiratory and cardiovascular health effects. Journal of Exposure Analysis and Environmental Epidemiology. 2001; 11: 490-500.
2000
. Exposure of chronic obstructive pulmonary disease patients to particulate matter: Relationships between personal and ambient air concentrations. Journal of the Air and Waste Management Association. Taylor & Francis; 2000; 50: 1081–1094.
. Impact of antibodies to interferon-β during treatment of multiple sclerosis. In Drug Treatment of Multiple Sclerosis. Auckland: Adis International; 2000. pp. 89–108.
1999
. Lesion load reproducibility and statistical sensitivity of clinical trials in multiple sclerosis. Neurology. 1999; 52: 433-434.
. Neutralising antibodies to interferon-β in the treatment of multiple sclerosis: Cause for concern?. CNS Drugs. Springer; 1999; 11: 225–243.
. Development of a multiple sclerosis functional composite as a clinical trials outcome measure. Brain. Oxford Univ Press; 1999; 122: 871–882.
. Nonparametric two-sample comparisons of changes on ordinal responses. Journal of the American Statistical Association. Taylor & Francis; 1999; 94: 970–978.
. Natural killer cells in relapsing-remitting multiple sclerosis: the effect of treatment with interferon β-1B. Neurology. AAN Enterprises; 1999; 52: 351–359.
1998
. Acute effects of ambient inhalable particles in asthmatic and nonasthmatic children. American Journal of Respiratory and Critical Care Medicine. Am Thoracic Soc; 1998; 157: 1034–1043.
. A role for natural killer cells in the immunopathogenesis of multiple sclerosis. Journal of Neuroimmunology. Elsevier; 1998; 86: 123–133.
. Statistical methods for evaluating multiple sclerosis therapies. Seminars in Neurology. 1998; 18: 351–375.
1997
. Longitudinal analyses for magnetic resonance imaging outcomes in multiple sclerosis clinical trials. Journal of Biopharmaceutical Statistics. Taylor & Francis; 1997; 7: 501–531.
. Recommendations from the National Multiple Sclerosis Society clinical outcomes assessment task force. Annals of Neurology. Wiley Online Library; 1997; 42: 379–382.
1996
. Surveillance of clustering near point sources. Statistics in Medicine. Wiley Online Library; 1996; 15: 727–740.
. Statistical and design considerations for multiple sclerosis clinical trials. In Multiple Sclerosis: Advances in Clinical Trial Design, Treatment and Future Perspectives. London: Springer-Verlag; 1996. pp. 63–103.
. Clinical outcomes assessment in multiple sclerosis. Annals of Neurology. Wiley Online Library; 1996; 40: 469–479.
1995
. A likelihood ratio test for equality of deviations from randomness. Researches on Population Ecology. Springer; 1995; 37: 203–209.
1994
. Spatial association learning in hummingbirds. In Case Studies in Biometry. New York: John Wiley & Sons; 1994. pp. 159-187.
. Overdispersed Poisson regression models for studies of air pollution and human health. Canadian Journal of Statistics. Wiley Online Library; 1994; 22: 421–440.
1993
. Magnetic resonance imaging (MRI) as an outcome measure in multiple sclerosis. Journal of Neurological Rehabilitation. SAGE Publications; 1993; 7: 117–129.
1990
. Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. I. Clinical and MRI evaluation. Neurology. AAN Enterprises; 1990; 40: 479–486.
. A regression model with random effects for beer chemistry and Canadians' beer preferences. Canadian Journal of Statistics. Wiley Online Library; 1990; 18: 108–121.
1989
. Models for quantal response experiments over time. Biometrics. JSTOR; 1989; 45: 1299–1308.
. The effect of truncation on a sequential test for the drift of Brownian motion. Sequential Analysis. Taylor & Francis; 1989; 8: 169–190.
1988
. The variability of rainfall acidity revisited. Canadian Journal of Statistics. JSTOR; 1988; 16: 15–38.
. Objective criteria for in-vitro responses in human tumor colony-forming assays. Medical Decision Making. SAGE Publications; 1988; 8: 304–309.
1987
. Truncated sequential medical trials involving paired data. Canadian Journal of Statistics. Wiley Online Library; 1987; 15: 363–374.
1986
. Numerical solutions for Bayes sequential decision problems. SIAM Journal on Scientific and Statistical Computing. SIAM; 1986; 7: 46–59.
1985
. Sequential medical trials with ethical cost. In Proceedings of the Berkeley Conference in Honor of Jerzy Neyman and Jack Kiefer. Monterey: Wadsworth; 1985. pp. 521-538.
. Thiopental requirements may be increased in children re-anesthetized at least one year after recovery from extensive thermal injury. Anesthesia and Analgesia. LWW; 1985; 64: 1156–1160.
1984
. Relative efficiencies of goodness-of-fit procedures with truncated data. Canadian Journal of Statistics. Wiley Online Library; 1984; 12: 107–117.
1983
. Effects of leukotrienes B4 and C4 on coronary circulation and myocardial contractility. Surgery. 1983; 94: 267–275.
. Wasted ventilation measured in vitro with eight anesthetic circuits with and without inline humidification. Anesthesiology. 1983; 59: 442–446.
1982
. Leukotriene D4: a potent coronary artery vasoconstrictor associated with impaired ventricular contraction. Science. American Association for the Advancement of Science; 1982; 217: 841–843.
. Secondary hyperparathyroidism associated with dichloromethane diphosphonate treatment of Paget's disease. Journal of Clinical Endocrinology and Metabolism. The Endocrine Society; 1982; 55: 1100–1107.